Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2194 - Sarcopenia associated with a body mass index (BMI) > 25 kg/m<sup>2</sup> predicts severe acute toxicity of nivolumab and pembrolizumab in melanoma patients


09 Oct 2016


Poster display


Valentine Heidelberger


Annals of Oncology (2016) 27 (6): 379-400. 10.1093/annonc/mdw379


V. Heidelberger1, N. Kramkimel2, O. Huillard1, P. Boudou Rouquette1, J. Chanal2, J. Arrondeau1, N. Franck2, J. Alexandre1, B. Blanchet3, N. Dupin2, S. Aractingi2, F. Goldwasser1

Author affiliations

  • 1 Medical Oncology, Hôpital Cochin, 75014 - Paris/FR
  • 2 Dermatology, Hôpital Cochin, Paris/FR
  • 3 Functional Unit Of Pharmacokinetics And Pharmacochemistry, Hôpital Cochin, 75014 - Paris/FR


Abstract 2194


Anti PD-1 antibodies nivolumab and pembrolizumab are checkpoint inhibitors widely used in metastatic melanoma. Although less frequent than with anti-CTLA4 therapy, severe immune-related adverse events can occur. Since the dose is calculated in mg/kg, we hypothesized that patients with abnormal body composition resulting in reduced distribution volume may be overexposed. We studied whether body composition could predict early severe toxicity in patients with advanced melanoma receiving either nivolumab or pembrolizumab.


All melanoma patients treated with anti PD-1 between August 2014 and February 2016 in our center were retrospectively reviewed. Early severe toxicity was defined as any toxicity occurring in the first 3 months of treatment leading to definitive or temporary treatment discontinuation. Muscle mass was measured on CT scan performed closest to treatment initiation. Patients having a skeletal muscle index inferior to the median of the studied population were defined as sarcopenic.


71 patients were included (33 females; median age 65 years, range 22 to 91 years). 68% received pembrolizumab and 32% nivolumab. 30% of tumors harbored BRAF V600 mutations, 23% NRAS mutations and 39% were wild type. Anti PD-1 antibody was the first line therapy for 36% of the patients. 42 (59%) patients had a BMI > 25 kg/m2 and 10 (14%) had both sarcopenia and a BMI > 25 kg/m2. A total of 11 (15%) patients experienced severe acute toxicity: pneumonitis (n = 1), nephritis (n = 1), polymyositis (n = 1), hepatitis (n = 2), uveitis (n = 1), cytopenia (n = 3) or polyarthritis (n = 2). No toxic death occurred. These events occurred early, 72% following either the first or second infusion. Treatment discontinuation was definitive (n = 9) or temporary (n = 2). Sarcopenic patients with a BMI > 25 kg/m2 experienced more early severe toxicities: 40% of early severe toxicity (n = 4) among sarcopenic-overweight patients compared to 11% (n = 7) among the other patients (p = 0, 04).


Patients with sarcopenia and a BMI > 25 kg/m2 experienced significantly more early severe toxicities, suggesting an abnormally high exposure. Precautions should be taken when prescribing anti PD-1 antibodies in this subset of patients.

Clinical trial identification

Legal entity responsible for the study

Hôpital Cochin APHP


Hôpital Cochin APHP


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings